RT Journal Article
SR Electronic
T1 Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.21.22279047
DO 10.1101/2022.08.21.22279047
A1 Zeng, Ruijie
A1 Ma, Yuying
A1 Zhang, Lijun
A1 Luo, Dongling
A1 Jiang, Rui
A1 Wu, Huihuan
A1 Zhuo, Zewei
A1 Yang, Qi
A1 Li, Jingwei
A1 Leung, Felix W
A1 Duan, Chongyang
A1 Sha, Weihong
A1 Chen, Hao
YR 2024
UL http://medrxiv.org/content/early/2024/05/07/2022.08.21.22279047.abstract
AB Adverse effects of proton pump inhibitors (PPIs) have raised wide concerns. The association of PPIs with influenza is unexplored, while that with pneumonia or COVID-19 remains controversial. Our study aims to evaluate whether PPI use increases the risks of these respiratory infections. The current study included 160,923 eligible participants at baseline who completed questionnaires on medication use, which included PPI or histamine-2 receptor antagonist (H2RA), from the UK Biobank. Cox proportional hazards regression and propensity score-matching analyses were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). Comparisons with H2RA users were tested. PPI use was associated with increased risks of developing influenza (HR 1.32, 95%CI 1.12-1.56) and pneumonia (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.26-1.59). In contrast, the risk of COVID-19 infection was not significant with regular PPI use (HR 1.08, 95%CI 0.99-1.17), while the risks of severe COVID-19 (HR 1.19. 95%CI 1.11-1.27) and mortality (HR 1.37. 95%CI 1.29-1.46) were increased. However, when compared with H2RA users, PPI users were associated with a higher risk of influenza (HR 1.74, 95%CI 1.19-2.54), but the risks with pneumonia or COVID-19-related outcomes were not evident. In conclusion, PPI users are associated with increased risks of influenza, pneumonia, as well as COVID-19 severity and mortality compared to non-users, while the effects on pneumonia or COVID-19-related outcomes under PPI use were attenuated when compared to the use of H2RAs. Appropriate use of PPIs based on comprehensive evaluation is required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Natural Science Foundation of China (82171698, 82170561, 81300279, 81741067, 82100238), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Foreign Distinguished Teacher Program of Guangdong Science and Technology Department (KD0120220129), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was acquired from each participant, and ethical approval was obtained from the North West Multi-Center Research Ethics Committee (approval number: 11/NW/0382, 16/NW/0274, and 21/NW/0157). The current study has been approved under the UK Biobank project 83339.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UK Biobank data are available at https://www.ukbiobank.ac.uk/ after approval of application.ACE2angiotensin-converting enzyme 2BMIbody mass indexCIconfidence intervalCOVID-19Coronavirus Disease 2019DCAdirected acyclic graphGERDgastroesophageal reflux diseaseH2RAhistamine-2 receptor antagonistHRhazard ratioIQRinterquartile rangeNSAIDSnon-aspirin non-steroidal anti-inflammatory drugsPPIproton pump inhibitorSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDstandard deviation.